| Journal | Journal of psychiatric research |
| Study Type | Clinical Study |
| Population | Human participants |
This scoping review highlights critical gaps in how we measure and understand cannabis use patterns in patients with psychosis and schizophrenia. With cannabis legalization expanding and product potency increasing, clinicians need better frameworks to assess and monitor cannabis use in this vulnerable population.
This scoping review examined 10 studies (2,631 participants) published after 2016 to characterize cannabis use patterns in schizophrenia spectrum disorders, supplemented by a case series from recent inpatient data. The review found significant methodological inconsistencies across studies, with no standardized measurement approaches and wide variation in reported use frequency and quantity (0.6-3.4 joints per day). Most studies showed at least a minority of participants using cannabis very frequently, but none were specifically designed to track cannabis use patterns over time. The lack of standardized assessment tools represents a major limitation for both research and clinical practice.
“What strikes me most is how poorly equipped we are to meaningfully assess cannabis use in patients with psychosis – we’re flying blind with inconsistent measures while cannabis products become more potent. This review confirms what I see clinically: we need standardized assessment tools that account for modern cannabis products and consumption patterns.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- How much cannabis do patients with schizophrenia typically use?
- Should I be concerned about cannabis use in patients with first-episode psychosis?
- How should I assess cannabis use in my patients with psychotic disorders?
- Is the relationship between cannabis and psychosis well-established?
- What are the clinical implications of increasing cannabis legalization for psychotic disorders?
FAQ
How much cannabis do patients with schizophrenia typically use?
Cannabis use patterns vary widely among patients with schizophrenia spectrum disorders, with reported usage ranging from 0.6 to 3.4 joints per day. At least a minority of patients in each study used cannabis very frequently, indicating significant consumption levels in this population.
Should I be concerned about cannabis use in patients with first-episode psychosis?
Yes, cannabis use is associated with both the development of psychosis and symptom relapse in patients with schizophrenia spectrum disorders. This is particularly concerning as cannabis products have increased in potency and legalization has expanded access.
How should I assess cannabis use in my patients with psychotic disorders?
Current research shows that cannabis measurement methodology varies widely and most studies don’t use standardized measures. Clinicians should systematically assess quantity, frequency, and type of cannabis use, though standardized assessment tools for this population need further development.
Is the relationship between cannabis and psychosis well-established?
Yes, there is established evidence linking cannabis use to psychosis development and symptom relapse in schizophrenia spectrum disorders. However, this scoping review found limited recent research specifically characterizing cannabis use patterns over time in this vulnerable population.
What are the clinical implications of increasing cannabis legalization for psychotic disorders?
As U.S. states continue to legalize cannabis and product potency increases, clinicians need better understanding of cannabis use patterns in patients with schizophrenia spectrum disorders. This is crucial for developing appropriate monitoring and intervention strategies for this high-risk population.